HOME › DRUGS › BLINATUMOMAB
ACTIVE SUBSTANCE / INN

BLINATUMOMAB

Brand name(s): Blincyto, BLINCYTO
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
BLA125557
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ACTIVE SUBSTANCE
Blinatumomab
REGULATORS
FDA · EMA
SPONSORS / MAH
AMGEN, Amgen Europe B.V.
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
BLINCYTOBLA125557AMGENPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
BlincytoAmgen Europe B.V.Authorised23/11/2015Precursor Cell Lymphoblastic Leukemia-Lymphoma

FULL INTELLIGENCE ON BLINATUMOMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →